Cancerimmunotherapy research The cancer antigenic peptide database serves as a crucial resource for researchers investigating cancer immunology and developing novel immunotherapiesManufacturer and User Facility Device Experience (MAUDE .... These databases compile experimentally validated data on peptides that are recognized by the immune system in the context of cancer.The MAUDEdatabasehouses medical device reports submitted to the FDA by mandatory reporters (manufacturers, importers and device user facilities) and ... Such peptides, often referred to as tumor antigens or neoantigens, are essential for triggering anti-tumor immune responses and are key targets for therapeutic interventions like cancer vaccines and adoptive cell therapies. Understanding the landscape of these antigenic peptides is paramount for advancing precision oncology.
Cancer antigenic peptides are fragments of proteins that can be presented on the surface of cancer cells via MHC molecules, making them visible to T cells. These peptides can arise from mutated proteins (neoantigens) or from proteins that are aberrantly expressed in cancer cells but not in normal tissues (tumor-associated antigens).Description:Tumor T cell antigen databaseis a data source and analysis platform for cancer vaccine target discovery focusing on human tumor antigens that ... The identification and characterization of these peptides are fundamental to developing immunotherapies that can specifically target cancer cells while sparing healthy onesAntiTBPdb.
Several prominent databases provide comprehensive collections of cancer antigenic peptides and related datacaAtlasis a comprehensive resource for the selection and prioritization of peptides for immunogenicity testing and cancer immunotherapy development.. These resources are invaluable for researchers seeking to identify potential targets for immunotherapy.ASH Annual Meeting & Exposition
* Cancer Epitope Database and Analysis Resource (CEDAR): CEDAR offers a broad collection of cancer epitope and receptor data curated from scientific literature. It meticulously catalogs experimental findings on antibody and T cell peptidic epitopes, with a primary focus on studies conducted in humans and non-human primates related to cancer.
* Cancer Antigenic Peptide Database (CAPDb): This database, also known as CAPed, is a significant repository for experimentally validated tumor antigens.The Human Protein Atlas It aims to provide a comprehensive collection of data crucial for cancer immunology researchImmunogenic cryptic peptides dominate the antigenic ....
* caAtlas: caAtlas is designed as a comprehensive resource to aid in the selection and prioritization of peptides for immunogenicity testing and the development of cancer immunotherapies. It offers tools and data to help researchers identify the most promising peptide candidates.
* TumorAgDB1.0: This platform is specifically built for neoantigen screening and validation in tumor immunotherapy. It offers robust support for researchers working on the identification of tumor-specific neoantigens.
* Immune Epitope Database (IEDB): While broader than just cancer, the IEDB is a freely accessible resource that catalogs experimental data on antibody and T cell epitopes, including a substantial amount of data relevant to cancer researchKEGG PATHWAY Database.
Neoantigens represent a particularly promising class of tumor antigens. They are derived from mutations that occur specifically within a patient's tumor cells, meaning they are unique to the cancer and not present in normal tissues. This specificity makes them ideal targets for personalized cancer immunotherapies, as treatments can be tailored to an individual's specific set of neoantigens. Databases that focus on neoantigens, such as TumorAgDB1.0, are critical for the advancement of this personalized approach.KEGG PATHWAY Database
Cancer antigenic peptide databases typically contain information such as:
* Peptide sequences: The specific amino acid sequences of the antigenic peptides.
* Source proteins: The original proteins from which the peptides are derived.
* MHC binding predictions: Information on how well a peptide is likely to bind to specific MHC molecules, a key step in T cell recognitionThe Cancer Epitope Database and Analysis Resource ( ....
* Experimental validation: Data confirming that the peptide elicits an immune response, often from assays like ELISPOT or intracellular cytokine staining.
* Tumor association: Information indicating whether the peptide is overexpressed or unique to cancer cellsKEGG PATHWAY Database.
This data is instrumental for various applications, including the design of peptide-based vaccines, the selection of targets for adoptive T cell therapy, and the development of diagnostic tools for cancer.
Despite the significant progress, challenges remain. The sheer volume of potential peptides and the complexity of the immune system require sophisticated computational tools for prediction and validation.A comprehensive proteogenomic pipeline for neoantigen ... Furthermore, understanding the immunogenicity of cryptic peptides and non-coding regions is an emerging area of research作者：G Zhang·被引用次数：53—We assembled TANTIGEN 2.0 by compiling the new data from theCancer Antigenic Peptide Database[24] and recent publications reporting .... Future databases and analytical platforms will likely integrate multi-omics data, including transcriptomics, proteomics, and immunogenomics, to provide a more holistic view of the tumor immunopeptidome and enhance the efficacy of cancer immunotherapies. The ongoing compilation and refinement of data within these specialized databases are vital for translating fundamental research into effective clinical treatments.It catalogsexperimental data on antibody and T cell peptidic epitopesprimarily studied in humans and non-human primates in the context of cancer disease.
Join the newsletter to receive news, updates, new products and freebies in your inbox.